Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Chris Boylan who wrote (9083)	3/10/1999 9:40:00 PM
From: Cacaito	Respond to of 17367

Institutional investors will increase the price of the stock with their heavy investments, not the small investors (this is not a e.com company). Only if they perceived that Bpi will be effective across the range of gram negative bacteria will the price pass double digits. Meningococcemia market is 3,000 patients a year in the USA, this justify not even the actual market value. My opinion: Bpi works and it works in all gram negatives. Xoma is working to make it work in gram positives and even Chlamydia (big market). My behavior: holding my shares, not buying more unless results are out and good.